US FDA clears Auriga's Liquadd for ADHD

US drugmaker Auriga Laboratories says that the Food and Drug Administration has approved Liquadd (dextroamphetamine sulfate) oral solution 5mg/5mL indicated for the treatment of attention-deficit hyperactivity disorder.

The ADHD market is valued at over $3.5 billion dollars, with 35 million prescriptions written annually. Dextroamphetamine is one of the most frequently prescribed molecules for the treatment of ADHD. "Liquadd will now provide physicians the proven efficacy of dextroamphetamine in a unique new oral solution form, with our key target consisting of the estimated 5% to 10% of patients that have difficulty swallowing pills," said Rick Coulon, executive vice president of sales and marketing at Auriga.

"We are excited about expanding the treatment options available to physicians by providing a dextroamphetamine treatment regimen in an easy-to-swallow form previously not available in the market," he noted, adding that the product will be launched during the second quarter.